Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. Reply

Sander F. Garrelfs, John M. Gansner, John C. Lieske

Research output: Contribution to journal › Comment/Letter to the editor › Academic

6 Citations (Scopus)

Original language	English
Pages (from-to)	e69
Journal	New England journal of medicine
Volume	385
Issue number	20
DOIs	https://doi.org/10.1056/NEJMc2107661
Publication status	Published - 11 Nov 2021

Access to Document

@article{2773b89112da425bae269c34d83d1e30,

title = "Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. Reply",

author = "Garrelfs, {Sander F.} and Gansner, {John M.} and Lieske, {John C.}",

year = "2021",

month = nov,

day = "11",

doi = "https://doi.org/10.1056/NEJMc2107661",

language = "English",

volume = "385",

pages = "e69",

journal = "New England journal of medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "20",

}

TY - JOUR

T1 - Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. Reply

AU - Garrelfs, Sander F.

AU - Gansner, John M.

AU - Lieske, John C.

PY - 2021/11/11

Y1 - 2021/11/11

UR - http://www.scopus.com/inward/record.url?scp=85121726283&partnerID=8YFLogxK

U2 - https://doi.org/10.1056/NEJMc2107661

DO - https://doi.org/10.1056/NEJMc2107661

M3 - Comment/Letter to the editor

C2 - 34758265

SN - 0028-4793

VL - 385

SP - e69

JO - New England journal of medicine

JF - New England journal of medicine

IS - 20

ER -